Related Experiment Videos
Gentamicin clearance during continuous arteriovenous hemodiafiltration.
1Intensive Therapy Unit, Royal North Shore Hospital, Sydney, Australia.
Critical Care Medicine
|May 1, 1992
Summary
Predicting gentamicin dosing during continuous arteriovenous hemodiafiltration (CAVHD) is challenging. While CAVHD clearance is related to ultrafiltrate flow, its variable contribution necessitates close monitoring of gentamicin levels.
Area of Science:
- Pharmacokinetics
- Nephrology
- Critical Care Medicine
Background:
- Gentamicin dosing requires adjustment in patients with acute renal failure undergoing continuous arteriovenous hemodiafiltration (CAVHD).
- Understanding gentamicin clearance during CAVHD is crucial for optimizing therapy and avoiding toxicity.
Purpose of the Study:
- To assess the feasibility of predicting gentamicin dosing requirements in patients on CAVHD.
- To quantify the contribution of CAVHD to the total body clearance of gentamicin.
Main Methods:
- Prospective study involving five adult patients with acute renal failure receiving both CAVHD and gentamicin therapy.
- Serial gentamicin concentrations in blood and ultrafiltrate/dialysate were measured to estimate CAVHD and total body clearance.
Main Results:
- CAVHD clearance of gentamicin was approximately 5.2 mL/min, representing about 25% of total body clearance.
- Gentamicin clearance via CAVHD demonstrated significant interpatient variability but was correlated with ultrafiltrate flow rate (r² = 0.81).
Conclusions:
- CAVHD clearance of gentamicin can be predicted based on ultrafiltrate flow rates.
- Due to its minor and variable role in overall gentamicin elimination, predicting precise dosing based on CAVHD clearance alone is not feasible.
- Close therapeutic drug monitoring of gentamicin concentrations is essential during CAVHD treatment.